Custom Manufacturing Accelerates Time to Market

As the life science industry faces increasing competition—as well as global regulatory and pricing pressures—outsourcing portions or all of manufacturing is becoming increasingly prevalent....

GENcast: The Quiet Voice of Immunotherapy That’s Starting to Be Heard

In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.

Moving the Drug Pipeline Forward with Mechanistic Modeling

In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully.

Impact of COVID-19 on the Life Science Industry

In this sponsored GENcast listen to a conversation with Dr. Klaus Lun, Executive Vice President of Life Science Business for Tecan, provide his perspective on global developments pertaining to COVID-19 and other timely topics.

Helping Biosimilars Emerge into Global Markets Takes a Practiced Hand

Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...

Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development

In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully.

GENcast: 3D Cell Models Push Drug Discovery Screening into High Gear

In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.

Virtual Collaborations Push Pharma Forward During Pandemic

With regions of the world cycling through societal re-openings and shutdowns due to the ongoing coronavirus pandemic, pharma and life science companies are tasked...